Canaccord Genuity initiated coverage of Seer with a Buy rating and a $4 price target, citing rising adoption of the firm’s proteomics technology and ongoing product improvements. Analyst Kyle Mikson pointed to growing publication use, lower per-sample costs, and an upgrade trajectory aimed at reducing throughput and unit-economics friction. Seer’s Proteograph platform uses nanoparticles to enrich proteins before downstream mass spectrometry, with the thesis that it expands protein capture across a broader dynamic range and improves reproducibility. Mikson’s note highlights Seer’s movement toward large, population-scale proteomic and proteogenomic studies, including a previously announced effort analyzing 20,000 plasma samples for early cancer detection. The report also referenced financial headwinds tied to uncertainty around NIH funding, as noted by Seer executives during the company’s Q4 2025 call. The near-term investor focus is whether the stated “next-generation detector” and planned new assay can further accelerate adoption in translational and clinical research settings.